--- title: "TalkSpace - CW25 | 8-K: FY2025 Q4 Revenue: USD 63 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/276336501.md" datetime: "2026-02-19T13:13:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276336501.md) - [en](https://longbridge.com/en/news/276336501.md) - [zh-HK](https://longbridge.com/zh-HK/news/276336501.md) --- # TalkSpace - CW25 | 8-K: FY2025 Q4 Revenue: USD 63 M Revenue: As of FY2025 Q4, the actual value is USD 63 M. EPS: As of FY2025 Q4, the actual value is USD 0.03. EBIT: As of FY2025 Q4, the actual value is USD 3.829 M. ### Financial Performance Summary #### Full Year 2025 Financial Highlights - **Total Revenue**: Talkspace, Inc. reported total revenue of $228,871 thousand, marking a 22.0% increase year-over-year. This growth included Payor revenue of $171,518 thousand (37.9% increase year-over-year), DTE revenue of $39,880 thousand (3.7% increase), and Consumer revenue of $17,473 thousand (29.5% decline). The total company revenue growth was +22% year-over-year, with Payor revenue growth at +38% year-over-year. - **Net Income**: Net income was $7,793 thousand, a significant increase of 578.8% compared to the prior year. - **Adjusted EBITDA**: Adjusted EBITDA grew by 127% year-over-year to $15,772 thousand. - **Operating Profit**: Income from operations was $3,152 thousand, a substantial improvement from a loss of -$4,497 thousand in 2024. - **Total Costs and Operating Expenses**: Total costs and operating expenses were $225,719 thousand, an 17.5% increase year-over-year. Operating expenses (OPEX) as a percentage of revenue declined to 42% from 48% a year ago. - **Cost of Revenue (excluding D&A)**: Cost of revenue, excluding depreciation and amortization, increased by 28.8% to $130,522 thousand. - **Research and Development**: Research and development expenses decreased by 7.2% to $9,544 thousand. - **Sales and Marketing**: Sales and marketing expenses increased by 6.5% to $53,803 thousand. #### Fourth Quarter 2025 Financial Highlights - **Total Revenue**: Total revenue reached $62,998 thousand, an increase of 29.3% year-over-year. This included Payor revenue of $47,663 thousand (40.8% increase year-over-year), DTE revenue of $11,634 thousand (21.8% increase), and Consumer revenue of $3,701 thousand (30.4% decline). - **Net Income**: Net income was $4,765 thousand, representing a 292.5% increase from the prior-year period. - **Adjusted EBITDA**: Adjusted EBITDA was $6,566 thousand, a 147% increase year-over-year. - **Operating Profit**: Income from operations was $3,829 thousand, a 572.9% increase year-over-year. - **Total Costs and Operating Expenses**: Total costs and operating expenses were $59,169 thousand, up 22.9% year-over-year. - **Cost of Revenue (excluding D&A)**: Cost of revenue, excluding depreciation and amortization, increased by 33.2% to $36,075 thousand. - **Research and Development**: Research and development expenses increased by 5.6% to $2,357 thousand. - **Sales and Marketing**: Sales and marketing expenses increased by 3.3% to $12,380 thousand. #### Operational Metrics - **Completed Payor Sessions**: The number of completed Payor sessions increased by 36% to 449.7 thousand in Q4 2025 and by 32% to 1,617.0 thousand for the full year 2025. - **Unique Active Payor Members**: Unique active Payor members grew by 30% to 124.1 thousand in Q4 2025. - **Patient Engagement**: Member funnel improvements resulted in a 49% year-over-year increase in patients completing a third session in the first month of care. Talkcast, with 76,000 episodes, drives a 20%+ higher likelihood to complete a second session. - **Network Expansion**: The psych provider network more than doubled. - **Strategic Initiatives**: The company launched national Tricare coverage, expanded Payor coverage with new Blues plans, secured a competitive national EAP win, and broadened its comprehensive care platform through the acquisition of Wisdo Health. It also deepened its relationship with Amazon by integrating with Amazon Pharmacy and launched Chapters, a women’s health platform. - **AI Development**: A beta version of TalkAI is demonstrating strong performance in adoption and outcomes. #### Cash Flow and Balance Sheet - **Cash and Cash Equivalents**: Cash and cash equivalents at year-end 2025 were $37,352 thousand. - **Marketable Securities**: Marketable securities at year-end 2025 were $55,234 thousand. - **Total Cash, Cash Equivalents, and Marketable Securities**: The company maintains approximately $93 million in cash, cash equivalents (including short-term marketable securities) for growth investments. - **Net Cash from Operating Activities**: Net cash provided by operating activities for the full year 2025 was $8,534 thousand. - **Net Cash used in Investing Activities**: Net cash used in investing activities for the full year 2025 was -$28,877 thousand. - **Net Cash used in Financing Activities**: Net cash used in financing activities for the full year 2025 was -$18,997 thousand. - **Net Decrease in Cash and Cash Equivalents**: The net decrease in cash and cash equivalents for the full year 2025 was -$39,340 thousand. - **Debt**: The company has $0 debt. - **Stock Repurchase**: Approximately $17 million of stock was repurchased under the share buyback plan. #### Outlook / Guidance Talkspace, Inc. expects 2026 revenue to be in the range of $275 million to $290 million, representing a year-over-year growth of +20% to +27%. Adjusted EBITDA is projected to be between $30 million and $35 million, reflecting a +90% to +122% year-over-year increase. The company plans to launch its proprietary AI agent later in 2026 and expects adoption of its care coordinator booking platform beta in early 2026. ### Related Stocks - [TALKW.US](https://longbridge.com/en/quote/TALKW.US.md) ## Related News & Research - [Big Tech's $1.2 Trillion Hyperscaler AI Bet Could Ignite the Next Semiconductor ETF Rally](https://longbridge.com/en/news/294843392.md) - [Lockup expiry will offer the next test of investor appetite for SpaceX shares](https://longbridge.com/en/news/294905336.md) - [The Wegovy pill's 'surprise miss' is one reason Novo Nordisk's stock is down](https://longbridge.com/en/news/294862814.md) - [ANALYSIS-Oracle Corp goes for high-stakes ratings gamble in AI strategy](https://longbridge.com/en/news/294853731.md) - [Palantir Is Growing Like Nvidia—Without Joining The AI Spending Race](https://longbridge.com/en/news/294845729.md)